Sold as Secretin-Ferring. Every FDA application for this active ingredient.
As of Nov 14, 2026, FDA lists 1 application for Secretin (sold as Secretin-Ferring), with 0 new uses approved and 0 published complete response letters.
| Secretin in Ex-situ Liver PerfusionLiver Transplantation · Erasmus Medical Center | Phase 1 / Phase 2 | Enrolling by invitation | Jun 16, 2026 |
| A Study Of Effect Of Secretin For In Injection (Chirostim) On Pancreatic Fluid Composition In Healthy SubjectsExocrine Pancreatic Insufficiency, Chronic Pancreatitis · Mayo Clinic | Phase 4 | Active, not recruiting | Dec 16, 2025 |
| The Influence of Secretin Stimulated Pancreatic Secretion on ctDNA Expression in Patients With Pancreatic Ductal Adenocarcinoma: The Role of Biomarkers in Determining the Prognosis of Pancreatic Ductal AdenocarcinomaPancreatic Adenocarcinoma, Pancreatic Cancer · Charles University, Czech Republic | — | Not yet recruiting | Feb 4, 2025 |
| The LINFU® U.S. Registry in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas)IPMN, Pancreatic, Pancreas Cancer · Adenocyte, LLC | — | Enrolling by invitation | Feb 26, 2024 |
| The LINFU® U.S. Registry in Patients With Clinical Signs and/or Symptoms of DiseasePancreatic Cancer, Jaundice · Adenocyte, LLC | — | Not yet recruiting | Feb 26, 2024 |
| The LINFU® U.S. Registry for the in the General Population Without Risk FactorsPancreatic Cancer, Pancreatic Ductal Adenocarcinoma · Adenocyte, LLC | — | Not yet recruiting | Feb 26, 2024 |
| Imaging Biomarkers of Pancreatic Function and DiseasePancreatitis, Diabetes Mellitus · Children's Hospital Medical Center, Cincinnati | Phase 4 | Enrolling by invitation | Dec 21, 2022 |
| Secretin in RefeedingAnorexia in Adolescence · University of California, Los Angeles | — | Recruiting | Feb 11, 2022 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| — | Secretin-FerringNDA 18290 | Ferring | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
